Syndax Pharmaceuticals Inc.

SNDX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001395937

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $529.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Feb 26, 2026 253 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026
Last close	$9.32 2026-11-05; market equity $839.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo? (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products. Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 89.1						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	6.0%	(6.6%)		89.1	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 58.3						
Twelve-month failure probability	0.34%	0.07%		75.8	249	2026-09-30
Altman Z double-prime	(7.54)	(0.37)		57.9	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.40x	2.94x		41.2	828	2025-12-31
Growth and financing, sleeve percentile 40.9						
Revenue growth, three-year compound	not computable	10.0%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 7						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	2.1%	2.2%		47.2	696	2025-12-31
Net share issuance, one year	2.5%	2.5%		34.7	630	2026-02-23

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	37.2%	(2.1%)	73
Distance from 52-week high	(62.7%)	(30.4%)	19
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(38.3%)	(1.0%)	17
Book value to price	(0.02)	0.29	10
Sales to price	0.20	0.30	40
Composite equity issuance, five years	62.4%	21.4%	68
Relative strength against the sector, log excess return	0.15	(0.19)	73

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$135.9M
Operating cash flow, four quarters	-$177.4M
Months of runway	9.2
Days since last periodic filing	4 (10-Q received Nov 2, 2026)
Median daily dollar volume, 63 sessions	$28.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$285.4M	2025-12-31	2026-02-26	10-K	26-076536
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$323.0M	2025-12-31	2026-02-26	10-K	26-076536
3	assets	us-gaap:Assets	$529.7M	2025-12-31	2026-02-26	10-K	26-076536
4	assets	us-gaap:Assets	$724.8M	2024-12-31	2026-02-26	10-K	26-076536
5	current assets	us-gaap:AssetsCurrent	$528.1M	2025-12-31	2026-02-26	10-K	26-076536
6	current liabilities	us-gaap:LiabilitiesCurrent	$120.1M	2025-12-31	2026-02-26	10-K	26-076536
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.5B	2025-12-31	2026-02-26	10-K	26-076536
8	operating income	us-gaap:OperatingIncomeLoss	-$273.1M	2025-12-31	2026-02-26	10-K	26-076536
9	book equity	us-gaap:StockholdersEquity	$64.6M	2025-12-31	2026-02-26	10-K	26-076536
10	liabilities	us-gaap:Liabilities	$465.1M	2025-12-31	2026-02-26	10-K	26-076536
11	operating income	us-gaap:OperatingIncomeLoss	-$230.0M	2023-12-31	2026-02-26	10-K	26-076536
12	interest expense	us-gaap:InterestExpense	$208,000	2023-12-31	2024-02-27	10-K	24-021253
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$172.4M	2025-12-31	2026-02-26	10-K	26-076536
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$23.7M	2024-12-31	2026-02-26	10-K	26-076536
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2023-12-31	2026-02-26	10-K	26-076536
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$139.7M	2021-12-31	2024-02-27	10-K	24-021253
17	assets	us-gaap:Assets	$612.9M	2023-12-31	2025-03-03	10-K	25-030394
18	assets	us-gaap:Assets	$497.2M	2022-12-31	2024-02-27	10-K	24-021253
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,200,596	2026-02-23	2026-02-26	10-K	26-076536
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	86,024,394	2025-02-24	2025-03-03	10-K	25-030394

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.